title: Industry perspective on the medical risk of visible particles in injectable drug products.
authors.forename: Stan
authors.initials: S
authors.lastname: Bukofzer
authors.forename: John
authors.initials: J
authors.lastname: Ayres
authors.forename: Anna
authors.initials: A
authors.lastname: Chavez
authors.forename: Minerva
authors.initials: M
authors.lastname: Devera
authors.forename: Jahanvi
authors.initials: J
authors.lastname: Miller
authors.forename: Douglas
authors.initials: D
authors.lastname: Ross
authors.forename: John
authors.initials: J
authors.lastname: Shabushnig
authors.forename: Susan
authors.initials: S
authors.lastname: Vargo
authors.forename: Harry
authors.initials: H
authors.lastname: Watson
authors.forename: Rick
authors.initials: R
authors.lastname: Watson
mesh_terms: D004340:Drug Contamination / Q000517:prevention & control*; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D007262:Infusions, Intravenous / Q000592:standards; D007267:Injections; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000032:analysis / Q000592:standards*; D012307:Risk Factors
chemical_list: D004364:Pharmaceutical Preparations